Epstein-Barr virus-associated smooth muscle tumors after kidney transplantation: Treatment and outcomes in a single center

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages

  Tan, Chieh Suai ^a   Loh, Hwai Liang ^a   Foo, Marjorie Wai Yin ^a   Choong, Lina Hui Lin ^a   Wong, Kok Seng ^a   Kee, Terence Yi Shern ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

EBV associated smooth muscle tumors; Epstein Barr virus; Immunosuppression; Kidney; Malignancy; Post transplant complications

Indexed keywords

ACTIN; AZATHIOPRINE; CALDESMON; CYCLOSPORIN; DESMIN; IMMUNOGLOBULIN G; PREDNISOLONE; RAPAMYCIN;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED SMOOTH MUSCLE TUMOR; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MUSCLE TUMOR; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EBV-ASSOCIATED SMOOTH MUSCLE TUMORS; EPSTEIN-BARR VIRUS; IMMUNOSUPPRESSION; KIDNEY; MALIGNANCY; POST-TRANSPLANT COMPLICATIONS;

ADULT; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SIROLIMUS; SMOOTH MUSCLE TUMOR; SURVIVAL RATE;

EID: 84881544509     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12139     Document Type: Article

References (20)

1. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011: 306: 1891.
2. Le Bail B, Morel D, Merel P et al. Cystic smooth-muscle tumor of the liver and spleen associated with Epstein-Barr virus after renal transplantation. Am J Surg Pathol 1996: 20: 1418.
3. Sadahira Y, Moriya T, Shirabe T, Matsuno T, Manabe T. Epstein-Barr virus-associated post-transplant primary smooth muscle tumor of the liver: report of an autopsy case. Pathol Int 1996: 46: 601.
4. To KF, Lai FM, Wang AY et al. Posttransplant Epstein-Barr virus-associated myogenic tumors involving bone. Cancer 2000: 89: 467.
5. Uribe-Uribe NO, Aviles-Salas A, Orozco-Estevez H, Alberu J, Angeles-Angeles A. Leiomyosarcoma associated with Epstein-Barr virus in an adult with renal transplant. Rev Invest Clin 1998: 50: 255.
6. Ferri L, Fraser R, Gaboury L, Mulder D. Epstein-Barr virus-associated pulmonary leiomyosarcoma arising twenty-nine years after renal transplantation. J Thorac Cardiovasc Surg 2003: 126: 877.
7. Sprangers B, Smets S, Sagaert X et al. Posttransplant Epstein-Barr virus-associated myogenic tumors: case report and review of the literature. Am J Transplant 2008: 8: 253.
8. Al Hussain T, Haleem A, Alsaad KO. Synchronous hepatic, mesenteric and pulmonary Epstein-Barr virus-associated smooth muscle tumors in a renal transplant recipient. Clin Transplant 2010: 24: 579.
9. Jonigk D, Laenger F, Maegel L et al. Molecular and clinicopathological analysis of epstein-barr virus-associated posttransplant smooth muscle tumors. Am J Transplant 2012: 12: 1908.
10. Lee ES, Locker J, Nalesnik M et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995: 332: 19.
11. Ong KW, Teo M, Lee V et al. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res 2009: 15: 5350.
12. Vathsala A, Woo KT. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital. Clin Transpl 1999: 189.
13. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002: 12: 431.
14. Chan JK, Yip TT, Tsang WY et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994: 18: 938.
15. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003: 63: 917.
16. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005: 352: 1317.
17. Alberu J, Pascoe MD, Campistol JM et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011: 92: 303.
18. Toh HC, Teo M, Ong KW et al. Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumour. Lancet Oncol 2006: 7: 955.
19. Deyrup AT, Lee VK, Hill CE et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 2006: 30: 75.
20. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007: 13: 748.